RecruitingPhase 2NCT07150845
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis
Sponsor
Evommune, Inc.
Enrollment
120 participants
Start Date
Aug 26, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Chronic AD that has been present for ≥6 months
- Validated-Investigator's Global Assessment score of ≥3
- EASI of ≥16
- BSA of AD involvement of ≥10%
Exclusion Criteria4
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
- Use of certain medications
- Presence of skin comorbidities or other condition(s) that may interfere with study assessments
- Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEVO756
Dose 1
DRUGEVO756
Dose 2
DRUGEVO756
Dose 3
DRUGPlacebo control
Placebo control
Locations(29)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07150845